PMID- 20199521
OWN - NLM
STAT- MEDLINE
DCOM- 20101124
LR  - 20171116
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 122
IP  - 3
DP  - 2010 Sep
TI  - Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label 
      extension study.
PG  - 202-8
LID - 10.1111/j.1600-0404.2010.01334.x [doi]
AB  - OBJECTIVE: This open-label extension evaluated the long-term efficacy and 
      tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had 
      previously completed a 12-week double-blind study. MATERIALS AND METHODS: In 
      total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic 
      drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was 
      assessed by seizure frequency; tolerability by adverse events (AEs) and 
      laboratory tests. RESULTS: Overall, patients were treated with rufinamide for a 
      median (range) of 432 (10-1149) days. Reductions in seizure frequency were 
      observed throughout the study; during the last 12 months of treatment, 41.0% and 
      47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure 
      frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia 
      (25.8%). CONCLUSIONS: In this open-label extension, rufinamide appeared to be an 
      effective long-term adjunctive therapy for the treatment of LGS-associated 
      seizures in children and young adults.
FAU - Kluger, G
AU  - Kluger G
AD  - BHZ Vogtareuth, Vogtareuth, Germany.
FAU - Glauser, T
AU  - Glauser T
FAU - Krauss, G
AU  - Krauss G
FAU - Seeruthun, R
AU  - Seeruthun R
FAU - Perdomo, C
AU  - Perdomo C
FAU - Arroyo, S
AU  - Arroyo S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100301
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Anticonvulsants)
RN  - 0 (Triazoles)
RN  - WFW942PR79 (rufinamide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticonvulsants/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Drug Therapy, Combination/methods
MH  - Epilepsy/*drug therapy
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Treatment Outcome
MH  - Triazoles/*therapeutic use
MH  - Young Adult
EDAT- 2010/03/05 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/03/05 06:00
PHST- 2010/03/05 06:00 [entrez]
PHST- 2010/03/05 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - ANE1334 [pii]
AID - 10.1111/j.1600-0404.2010.01334.x [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2010 Sep;122(3):202-8. doi: 10.1111/j.1600-0404.2010.01334.x. 
      Epub 2010 Mar 1.